MediciNova Inc (MNOV)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:MediciNova Inc (MNOV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012278
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
MediciNova Inc (MediciNova) is a biopharmaceutical company, which focuses on acquiring, and developing novel, small-molecule therapeutics for the treatment of neurology, respiratory, and liver diseases. MediciNova’s developmental pipeline includes core programs such as MN-001, for the treatment of nonalcoholic steatohepatitis; MN-166, for neurological disorders; and MN-221, for respiratory diseases. The company’s non-core programs include MN-001 being developed for two indications, namely, bronchial asthma and interstitial cystitis; MN-029 for the treatment of solid tumors; and MN-221 for the treatment of preterm labor. It has partnerships with various companies such as Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Angiogene Pharmaceuticals Ltd and Meiji Seika Kaisha Ltd., to develop and commercialize its products. MediciNova is headquartered in California, the US.

MediciNova Inc (MNOV) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
MediciNova Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
MediciNova Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
MediciNova Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
MediciNova Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
MediciNova Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
MediciNova Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
MediciNova Enters into Agreement with US Department of Veterans and Oregon Health & Science 10
MediciNova Forms Joint Venture With Zhejiang Medicine 11
Licensing Agreements 12
MediciNova Enters Into Licensing Agreement With University of Colorado Boulder For Ibudilast 12
Equity Offering 13
MediciNova Plans to Raise up to USD200 Million in Public Offering of Securities 13
MediciNova to Raise up to USD30 Million in Public Offering of Shares 14
MediciNova Raises USD17.5 Million in Public Offering of Shares 15
MediciNova Completes First Tranche Of Public Offering Of Common Stock For US$2.8 Million 16
MediciNova Completes First Tranche Of Private Placement Of Common Stock For US$1 Million 17
MediciNova Completes Private Placement Of Common Stock And Preferred Stock For US$7.5 Million 18
MediciNova Completes An Underwritten Public Offering Of Units For US$8.4 Million 20
MediciNova Inc – Key Competitors 22
MediciNova Inc – Key Employees 23
MediciNova Inc – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Corporate Communications 25
Nov 09, 2017: MediciNova Appoints Hideki Nagao to its Board of Directors 25
Dec 14, 2016: MediciNova Added to NASDAQ Biotechnology Index 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
MediciNova Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
MediciNova Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
MediciNova Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
MediciNova Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
MediciNova Inc, Deals By Therapy Area, 2011 to YTD 2017 8
MediciNova Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
MediciNova Enters into Agreement with US Department of Veterans and Oregon Health & Science 10
MediciNova Forms Joint Venture With Zhejiang Medicine 11
MediciNova Enters Into Licensing Agreement With University of Colorado Boulder For Ibudilast 12
MediciNova Plans to Raise up to USD200 Million in Public Offering of Securities 13
MediciNova to Raise up to USD30 Million in Public Offering of Shares 14
MediciNova Raises USD17.5 Million in Public Offering of Shares 15
MediciNova Completes First Tranche Of Public Offering Of Common Stock For US$2.8 Million 16
MediciNova Completes First Tranche Of Private Placement Of Common Stock For US$1 Million 17
MediciNova Completes Private Placement Of Common Stock And Preferred Stock For US$7.5 Million 18
MediciNova Completes An Underwritten Public Offering Of Units For US$8.4 Million 20
MediciNova Inc, Key Competitors 22
MediciNova Inc, Key Employees 23
MediciNova Inc, Subsidiaries 24

★海外企業調査レポート[MediciNova Inc (MNOV)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Amgen Inc (AMGN)-製薬・医療分野:企業M&A・提携分析
    Summary Amgen Inc (Amgen) is a biotechnology company that discovers, develops, manufactures and markets innovative human therapeutics to improve the lives of patients suffering from serious diseases. It develops novel medicines in six focused therapeutic areas including cardiovascular disease, oncol …
  • Black Stone Minerals LP (BSM):企業の財務・戦略的SWOT分析
    Summary Black Stone Minerals LP (Black Stone) is a mining and minerals exploration and development company that explores and produces mineral deposits. The company's services include participating on a working interest basis when economics are favorable, leasing minerals to exploration and productio …
  • Polycom Inc:企業の戦略的SWOT分析
    Polycom Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Israel Chemicals Ltd.:企業のM&A・事業提携・投資動向
    Israel Chemicals Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Israel Chemicals Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Scilex Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Scilex Pharmaceuticals Inc (Scilex Pharma), a subsidiary of Sorrento Therapeutics Inc is a developer of pharmaceutical products. The company develops and commercializes branded pharmaceutical products for the treatment of pain. Its technologies include drug delivery and proprietary patch tec …
  • CytImmune Sciences Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary CytImmune Sciences Inc (CytImmune) is a clinical stage nanomedicine company that discovers, develops, and commercializes tumor-targeted therapies. The company develops nanotherapy platform, Aurimune, a tumor-targeted trojan horse. Its Aurimune binds TNF receptors on blood vessel cells at the …
  • Dongfang Electric Corporation Ltd (1072)-エネルギー分野:企業M&A・提携分析
    Summary Dongfang Electric Corporation Ltd (DEC) a subsidiary of Dongfang Electric Corporation, is a power equipment and services company. It designs, manufactures, and sells power generation equipment, including turbines for hydro, thermal, and nuclear power generation, wind turbine generator sets, …
  • Ontario Teachers’ Pension Plan:企業のM&A・事業提携・投資動向
    Ontario Teachers' Pension Plan - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Ontario Teachers' Pension Plan Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • PolyNovo Ltd (PNV)-医療機器分野:企業M&A・提携分析
    Summary PolyNovo Ltd (PolyNovo), formerly Calzada Ltd is a medical device company that develops, manufactures and commercializes biodegradable polymers for use in medical devices. The company offers products such as biodegradable temporizing matrix and negative pressure wound therapy dressing system …
  • Azomures SA:企業の戦略的SWOT分析
    Azomures SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • The People’s Insurance Company (Group) of China Limited:企業の戦略・SWOT・財務情報
    The People's Insurance Company (Group) of China Limited - Strategy, SWOT and Corporate Finance Report Summary The People's Insurance Company (Group) of China Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the compan …
  • Traverse Biosciences Inc-製薬・医療分野:企業M&A・提携分析
    Summary Traverse Biosciences Inc (Traverse Biosciences) is an independent bioscience company that commercializes drug candidates for the treatment of inflammatory diseases and age-related conditions affecting humans and companion animals. The company’s lead candidate TRB-N0224 is developed for canin …
  • Temasek Holdings (Private) Ltd:企業の戦略・SWOT・財務分析
    Temasek Holdings (Private) Ltd - Strategy, SWOT and Corporate Finance Report Summary Temasek Holdings (Private) Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Siemens Medical Solutions USA Inc:企業のM&A・事業提携・投資動向
    Siemens Medical Solutions USA Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Siemens Medical Solutions USA Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • Allahabad Bank (ALBK):企業の財務・戦略的SWOT分析
    Allahabad Bank (ALBK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • PetSmart, Inc.:企業の戦略・SWOT・財務情報
    PetSmart, Inc. - Strategy, SWOT and Corporate Finance Report Summary PetSmart, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • NorthWestern Corporation:企業の戦略・SWOT・財務分析
    NorthWestern Corporation - Strategy, SWOT and Corporate Finance Report Summary NorthWestern Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • GETECH Group plc (GTC):企業の財務・戦略的SWOT分析
    Summary Getech Group Plc (Getech) is an oil and gas service company that offers geological and geophysical services. The company’s services include regional reports, globe, commissions and global gravity and magnetic data solutions. Its in-house specialties comprise airborne geophysics, potential fi …
  • Covagen AG-製薬・医療分野:企業M&A・提携分析
    Summary Covagen AG (Covagen), a subsidiary of Cilag GmbH International is a biopharmaceutical company specializing in the development of multispecific protein therapeutics through the FynomAb technology. The company’s pipeline products include COVA 322, a bispecific anti-tumor necrosis factor alpha …
  • G1 Therapeutics Inc (GTHX)-製薬・医療分野:企業M&A・提携分析
    Summary G1 Therapeutics Inc (G1 Therapeutics), formerly G Zero Therapeutics Inc is a healthcare company that develops novel, and small molecule therapies. The company pipeline products include CDK4/6, trilaciclib G1T28 a drug candidate; G1T38 a potential best compound, and G1T48. It undertakes disco …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆